StocksMedium•30 September 2026•
1 min read
Abbott Launches SimpleScreen CRC Blood-Based Colorectal Cancer Test
Key Facts
1Abbott Laboratories launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in adults aged 45 and older.
2The new test is covered by Medicare and aims to increase screening rates by offering a convenient alternative to traditional methods.
Abbott Laboratories launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in adults aged 45 and older. Pluang reported that the new test is covered by Medicare and aims to increase screening rates by offering a convenient alternative to traditional methods.
ABT closed at $100.95 on September 29, 2026, as the stock faces selling pressure despite the product launch. The test detects cancer signals via circulating cell-free DNA, providing an option for patients who decline traditional screening methods such as colonoscopies.